{"id":62,"date":"2021-07-29T05:31:32","date_gmt":"2021-07-29T05:31:32","guid":{"rendered":"https:\/\/bioacq.wpengine.com\/?page_id=62"},"modified":"2022-04-12T00:03:50","modified_gmt":"2022-04-12T00:03:50","slug":"news-and-filings","status":"publish","type":"page","link":"https:\/\/bioacq.com\/?page_id=62","title":{"rendered":"News and filings"},"content":{"rendered":"\n<section class=\"wp-block-themeisle-blocks-advanced-columns alignfull has-1-columns has-desktop-equal-layout has-tablet-equal-layout has-mobile-equal-layout has-nogap-gap has-vertical-center\" id=\"wp-block-themeisle-blocks-advanced-columns-244374d7\"><div class=\"wp-block-themeisle-blocks-advanced-columns-overlay\"><\/div><div class=\"innerblocks-wrap\">\n<div class=\"wp-block-themeisle-blocks-advanced-column\" id=\"wp-block-themeisle-blocks-advanced-column-6cfc57bc\">\n<h1 id=\"wp-block-themeisle-blocks-advanced-heading-273962f7\" class=\"wp-block-themeisle-blocks-advanced-heading wp-block-themeisle-blocks-advanced-heading-273962f7\"><strong>News<\/strong><\/h1>\n<\/div>\n<\/div><\/section>\n\n\n\n<div class=\"wp-block-query is-layout-flow wp-block-query-is-layout-flow\"><ul class=\"wp-block-post-template is-layout-flow wp-block-post-template-is-layout-flow\"><li class=\"wp-block-post post-272 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"wp-block-post-date\"><time datetime=\"2022-06-13T00:56:00+00:00\">June 13, 2022<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=272\" target=\"_self\" >Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">NEW YORK\u00a0and\u00a0SOUTH SAN FRANCISCO, Calif.,\u00a0June 13, 2022\u00a0\/PRNewswire\/ &#8212; Biotech Acquisition Company (NASDAQ:\u00a0BIOT) (&#8220;BAC&#8221;), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (&#8220;Blade&#8221;), a biopharmaceutical company based in\u00a0South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=272\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-269 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"wp-block-post-date\"><time datetime=\"2022-05-31T03:50:00+00:00\">May 31, 2022<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=269\" target=\"_self\" >Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Extraordinary General Meeting of BAC&#8217;s shareholders postponed until&nbsp;June 3, 2022, at&nbsp;10:00 a.m., Eastern Time NEW YORK&nbsp;and&nbsp;SOUTH SAN FRANCISCO,&nbsp;May 31, 2022&nbsp;\/PRNewswire\/ &#8212; Biotech Acquisition Company (NASDAQ: BIOT) (&#8220;BAC&#8220;), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and&nbsp;Blade Therapeutics, Inc. (&#8220;Blade&#8221;), a biopharmaceutical company based in&nbsp;South San Francisco, Calif., today announced the postponement&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=269\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-265 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"wp-block-post-date\"><time datetime=\"2022-05-09T01:30:00+00:00\">May 9, 2022<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=265\" target=\"_self\" >Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC\u2019s Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity Facility<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Extraordinary General Meeting of BAC\u2019s shareholders is scheduled for&nbsp;June 1, 2022, at&nbsp;10:00 a.m., Eastern Time Post-closing company will be renamed \u201cBlade Biotherapeutics, Inc.\u201d upon Business Combination closing, with common stock and warrants expected to trade on the Nasdaq Global Market under ticker symbols \u201cBBTX\u201d and \u201cBBTXW\u201d Post-closing company has secured up to&nbsp;$75 million&nbsp;in financing under&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=265\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-261 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"wp-block-post-date\"><time datetime=\"2022-04-04T12:02:00+00:00\">April 4, 2022<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=261\" target=\"_self\" >Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">NEW YORK,&nbsp;April 4, 2022 &#8211; Biotech Acquisition Company (NASDAQ:&nbsp;BIOT) (&#8220;BAC&#8220;), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, the first amendment to its registration statement on Form S-4, filed on&nbsp;March 15, 2022&nbsp;(as amended, the &#8220;registration statement&#8221;), relating&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=261\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-257 post type-post status-publish format-standard hentry category-uncategorized\">\n<div class=\"wp-block-post-date\"><time datetime=\"2022-04-04T06:36:00+00:00\">April 4, 2022<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=257\" target=\"_self\" >Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">U.S. Food and Drug Administration (FDA) provides feedback necessary to proceed into a phase 2 proof of concept (PoC)\/dose ranging study of cudetaxestat in patients with idiopathic pulmonary fibrosis (IPF) Company plans to advance cudetaxestat, a non-competitive inhibitor of autotaxin, into a 26-week phase 2 clinical trial in the second quarter of 2022 SOUTH SAN&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=257\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-241 post type-post status-publish format-standard hentry category-news category-press-release\">\n<div class=\"wp-block-post-date\"><time datetime=\"2022-03-16T02:53:00+00:00\">March 16, 2022<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=241\" target=\"_self\" >Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">New York, NY, March 16, 2022&nbsp;\u2013 Biotech Acquisition Company (NASDAQ: BIOT) (\u201cBAC\u201d), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, a registration statement on Form S-4 relating to its previously announced proposed business combination with Blade Therapeutics,&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=241\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-236 post type-post status-publish format-standard hentry category-news category-press-release\">\n<div class=\"wp-block-post-date\"><time datetime=\"2022-01-03T00:00:00+00:00\">January 3, 2022<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=236\" target=\"_self\" >Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">New York, NY, January 3, 2022 \u2013 Biotech Acquisition Company (NASDAQ: BIOT) (\u201cBAC\u201d), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential submission to the United States Securities and Exchange Commission (\u201cSEC\u201d), for receipt by the SEC on December 27, 2021, of a draft&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=236\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-216 post type-post status-publish format-standard hentry category-news category-press-release\">\n<div class=\"wp-block-post-date\"><time datetime=\"2021-11-08T00:00:00+00:00\">November 8, 2021<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=216\" target=\"_self\" >Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">NEW YORK and SOUTH SAN FRANCISCO, Calif., November 3, 2021 \u2013 Biotech Acquisition Company (Nasdaq: BIOT) (\u201cBAC\u201d), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (\u201cBlade\u201d), a biopharmaceutical company based in South San Francisco, Calif., announced today that they have entered into a definitive merger agreement&#8230;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=216\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-183 post type-post status-publish format-standard hentry category-news category-press-release\">\n<div class=\"wp-block-post-date\"><time datetime=\"2021-03-15T15:45:00+00:00\">March 15, 2021<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=183\" target=\"_self\" >Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2021<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Biotech Acquisition Company (NASDAQ:\u00a0BIOTU) (the &#8220;Company&#8221;) announced that, commencing\u00a0March 18, 2021, holders of the units sold in the Company&#8217;s initial public offering may elect to separately trade the Company&#8217;s Class\u00a0A ordinary shares (&#8220;Class A Ordinary Shares&#8221;) and warrants included in the units. No fractional warrants will be issued upon separation of the units and only&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=183\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><li class=\"wp-block-post post-184 post type-post status-publish format-standard hentry category-news category-press-release\">\n<div class=\"wp-block-post-date\"><time datetime=\"2021-01-28T01:28:00+00:00\">January 28, 2021<\/time><\/div>\n\n<h2 class=\"wp-block-post-title\"><a href=\"https:\/\/bioacq.com\/?p=184\" target=\"_self\" >Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering.<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Biotech Acquisition Company (the \u201cCompany\u201d) announced today that it has closed its initial public offering of 23,000,000 units, including 3,000,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000&#8230;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/bioacq.com\/?p=184\"><strong>Read More &gt;&gt;<\/strong><\/a><\/p><\/div>\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/li><\/ul><\/div>\n\n\n\n<section class=\"wp-block-themeisle-blocks-advanced-columns alignfull has-1-columns has-desktop-equal-layout has-tablet-equal-layout has-mobile-equal-layout has-nogap-gap has-vertical-center\" id=\"wp-block-themeisle-blocks-advanced-columns-00773d70\"><div class=\"wp-block-themeisle-blocks-advanced-columns-overlay\"><\/div><div class=\"innerblocks-wrap\">\n<div class=\"wp-block-themeisle-blocks-advanced-column\" id=\"wp-block-themeisle-blocks-advanced-column-21b1b3a4\">\n<h1 id=\"wp-block-themeisle-blocks-advanced-heading-47ee0331\" class=\"wp-block-themeisle-blocks-advanced-heading wp-block-themeisle-blocks-advanced-heading-47ee0331\"><strong>Filings<\/strong><\/h1>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-primary\"><a class=\"wp-block-button__link has-accent-background-color has-background\" href=\"https:\/\/www.sec.gov\/edgar\/browse\/?CIK=1825413&amp;owner=exclude\" target=\"_blank\" rel=\"noreferrer noopener\">SEC Filings<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-primary\"><a class=\"wp-block-button__link has-accent-background-color has-background\" href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1825413\/000121390021057189\/ea148645ex99-1_biotechacqui.htm\" target=\"_blank\" rel=\"noreferrer noopener\">Presentation<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-accent-background-color has-background\" href=\"https:\/\/bioacq.com\/wp-content\/uploads\/2022\/03\/EA4113E_Biotech-Acquisition-Company_S-4_Clean_As-Filed.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">S-4<\/a><\/div>\n\n\n\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-accent-background-color has-background\" href=\"https:\/\/bioacq.com\/wp-content\/uploads\/2022\/04\/ea158285-8k425_biotech_ASFILED.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">8-K<\/a><\/div>\n<\/div>\n<\/div>\n<\/div><\/section>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<div class=\"wp-block-genesis-blocks-gb-columns gb-layout-service-2 gb-layout-columns-1 one-column gb-has-custom-background-color gb-columns-center alignfull\" style=\"padding-top:7%;padding-right:5%;padding-bottom:7%;padding-left:5%;background-color:#f1f1f1\"><div class=\"gb-layout-column-wrap gb-block-layout-column-gap-2 gb-is-responsive-column\" style=\"max-width:1200px\">\n<div class=\"wp-block-genesis-blocks-gb-column gb-block-layout-column\"><div class=\"gb-block-layout-column-inner\">\n<div style=\"margin-bottom:5%\" class=\"wp-block-genesis-blocks-gb-container gb-block-container\"><div class=\"gb-container-inside\"><div class=\"gb-container-content\" style=\"max-width:1170px\">\n<p class=\"has-black-color has-text-color wp-block-paragraph\" style=\"font-size:12px\"><strong><em>Cautionary Note Concerning Forward-Looking Statements<\/em><\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\" style=\"font-size:12px\"><em><em>This communication contains statements that constitute \u201cforward-looking statements,\u201d including with respect to the\u00a0anticipated use of the net proceeds from the\u00a0Company\u2019s initial public\u00a0offering. No assurance can be given that the\u00a0net proceeds will be used as indicated. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company\u2019s\u00a0prospectus relating to the offering, which is\u00a0filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d). Copies are available on the SEC\u2019s\u00a0website, www.sec.gov. The Company undertakes no obligation to update\u00a0its forward-looking\u00a0statements, except as required by law.<\/em><\/em><\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\" style=\"font-size:12px\"><strong><em>No Offer or Solicitation<\/em><\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\" style=\"font-size:12px\"><em>The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended.<\/em><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-62","page","type-page","status-publish","hentry"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/pages\/62","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bioacq.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62"}],"version-history":[{"count":0,"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/pages\/62\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}